NBIX•benzinga•
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $158
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 28, 2025 by benzinga